Download PDF
Exp Clin Endocrinol Diabetes 2003; 111(1): 47-48
DOI: 10.1055/s-2003-37501
Short Communication

J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York

Statins Can Inhibit Proliferation of Human Breast Cancer Cells in Vitro

H. Seeger 1 , D. Wallwiener 1 , A. O. Mueck 1
  • 1Section of Gynecological Endocrinology and Menopause, Department of Obstetrics and Gynecology, University of Tuebingen, Germany
Further Information

Publication History

Received: May 6, 2002 First decision: June 7, 2002

Accepted: July 17, 2002

Publication Date:
26 February 2003 (online)

Also available at
    Permissions and Reprints

Abstract

The effect of five statins, i.e. atorvastatin, fluvastatin, lovastatin, pravastatin and simvastatin was investigated on the proliferation of the human breast cancer cell line MCF-7. All statins except of pravastatin were able to inhibit cell proliferation up to 90 % at a concentration of 50 µM. Between the effective statins no significant difference was observed indicating a class-specific effect. These data suggest that statins may have clinical significance in the primary prevention of human breast cancer beyond their cholesterol-lowering effect. However, clinical proof must be awaited before drawing any further conclusions.

Key words

Statins - Cell proliferation - Human breast cancer cells

References

  • 1 Andreotti P E, Thornthwaite J T, Morse I S. ATP tumor chemosensitivity assay. Stanley PE, Kricka LJ Bioluminescence and Chemiluminescence: Current Status. Chichester; J. Wiley & Son 1991: 417-420
    Google Scholar
  • 2 Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier J P, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathway involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: in vitro study.  Carcinogenesis. 2001;  22 1139-48
    CrossrefPubMedGoogle Scholar
  • 3 Edwards P A, Ericsson J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway.  Annu Rev Biochem. 1999;  68 157-185
    CrossrefPubMedGoogle Scholar
  • 4 Gaw A, Packard C J, Shepherd J. Statins: The HMG CoA Reductase Inhibitors in Perspectives. London; Martin Dunitz 2000
    Google Scholar
  • 5 Hamelin B A, Turgeon J. Hydophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors.  TiPS. 1998;  19 26-37
    PubMedGoogle Scholar
  • 6 Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.  Clin Pharmacokinet. 2000;  39 397-412
    PubMedGoogle Scholar
  • 7 Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors.  Clin Pharmacokinet. 1997;  32 403-425
    PubMedGoogle Scholar
  • 8 Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins.  Science. 1999;  286 1946-1949
    CrossrefPubMedGoogle Scholar
  • 9 Simons M, Keller P. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons.  Proc Natl Acad Sci USA. 1998;  95 6460-6464
    CrossrefPubMedGoogle Scholar
  • 10 Takemoto M, Liao J K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.  Arterioscler Thromb Vasc Biol. 2001;  21 1712-1719
    CrossrefPubMedGoogle Scholar

MD, PhD, PH, Head of Section of Gynecological Endocrinology and Menopause A. O. Mueck

Department of Obstetrics and Gynecology

Calwerstraße 7

72076 Tuebingen

Germany

Fax: +49/7071294801

Email: endo.meno@med.uni-tuebingen.de

      >